



BOBCAPS

TRUST | INNOVATION | EXCELLENCE

DAILY TECHNICAL & DERIVATIVES REPORT

- Macro Pulse
- Market Snapshot
- India Key News
- Institutional Activity
- Index View
- Sectors & Stocks
- Key Moving Averages

14th October, 2026

Shantanu Vartak | Shantanu.Vartak@bobcaps.in

Research Analyst.



GLOBAL SCRIPS	LTP	CHANGE	% CHG
DJIA	51,670.10	-180.45	-0.35%
S&P 500	7,805.45	-1.79	-0.02%
NASDAQ 100	30,569.48	-95.22	-0.31%
FTSE 100	10,650.33	-5.95	-0.06%
NIKKEI (8:00 AM)	68,185.00	407.48	0.60%
HANG SENG (8:00 AM)	24,359.50	14.28	0.06%
GOLD	4,185.34	8.04	0.19%
SILVER	59.44	-0.10	-0.16%
BRENT OIL	106.57	0.88	0.83%
DOLLAR INDEX	101.93	-0.05	-0.05%
USD/INR	95.24	-0.04	-0.04%

*Closed

*Source: investing.com, moneycontrol.com

Global updates

- Oil prices rose as renewed attacks in the Middle East heightened uncertainty over the recovery of energy supplies through the Persian Gulf. **Brent crude** climbed above \$106 per barrel after declining 0.9% on Tuesday, while **WTI** advanced toward \$95.
- The **Nasdaq Composite** ended lower on Tuesday as chip stocks extended their recent losses, while investors assessed mixed quarterly results from Citigroup and other major U.S. banks. **Asian markets** rebounded after two consecutive sessions of losses, supported by expectations that the Federal Reserve may not need to raise interest rates aggressively next year.
- GIFT Nifty** trading at ~22,765.00 is indicating a negative start for the Indian market on Wednesday.



MARKET SNAPSHOT

INDIAN INDICES	LTP	CHANGE	% CHG
NIFTY 50	22,721.95	358.60	1.60%
SENSEX	73,033.78	1,109.10	1.54%
BANK NIFTY	55,481.05	563.05	1.03%
FIN NIFTY	25,228.55	362.20	1.46%
NIFTY MIDCAP 100	59,459.20	624.65	1.06%
NIFTY SMLCAP 100	19,447.40	21.60	0.11%
INDIA VIX	14.11	-1.14	-7.49%


INDEX	ADVANCE	DECLINE	UNCHANGED
NIFTY 50	46	4	0
NIFTY 500	367	132	1
NIFTY F&O	177	36	0

INDEX	SCRIPS ABOVE 50 DSMA	%
NIFTY 50	9	18%
NIFTY 500	109	22%

Highlights

- Nifty staged a sharp reversal on Tuesday, supported by a strong rally in the IT sector, with the Nifty IT index surging by more than 5% and leading the market recovery.
- HCLTECH (+8.42%) and TCS (+6.79%) emerged as Nifty's top two gainers, reflecting strong buying interest in IT heavyweights. The rally was broad-based, with buying interest extending across multiple sectors and supporting a sharp rebound in overall market sentiment.

MIDSM400 / NIFTY50 Ratio (last 20 trading sessions)





Polycab India

The National Company Law Appellate Tribunal (NCLAT), New Delhi, has stayed and kept in abeyance the October 7 order passed by the National Company Law Tribunal (NCLT), Ahmedabad, regarding the admission of a petition and initiation of the Corporate Insolvency Resolution Process (CIRP) against Polycab India in a case filed by Asier Metals under the Insolvency and Bankruptcy Code. The case relates to an alleged operational debt of Rs 2.79 crore.

Ujjivan Small Finance Bank

The bank's Board will meet on October 16 to consider the unaudited financial results for the quarter and half year ended September 2026. The Board will also consider raising funds through the preferential issue of equity shares.

Zydus Lifesciences

The US Food and Drug Administration (USFDA) inspected the company's manufacturing facility in Moraiya, Ahmedabad, from October 5 to 13. The inspection concluded with five observations.

Hyundai Motor India

Hyundai Motor Group announced a comprehensive investment strategy for India, committing \$15.5 billion between 2026 and 2032. The investment underscores India's position as a strategic core market for the Group's future growth, expansion into emerging markets and next-generation automotive innovation.

Bharat Electronics


The company has secured additional orders worth Rs 533 crore since September 17. The major orders include communication equipment, avionics, cybersecurity solutions, drones, jammers, software solutions, upgrades, spares and services.



INSTITUTIONAL ACTIVITY


*INR in Crores

Cash Segment	13-Oct-2026	MTD	YTD
FII Net Flows	-1,305.13	-42,792.12	-4,45,859.60
DII Net Flows	2,439.24	45,839.58	6,85,374.43



*INR in Crores

FII's F&O Flows	13-Oct-2026	MTD
Index Futures	959.82	-829.27
Index Options	1,044.32	-6,922.00
Stock Futures	4,559.70	15,490.37
Stock Options	33.16	-3,607.14






INDEX VIEW

NIFTY

Spot	22721.95
Futures	22834.80
Highest CE OI (27 th OCT)	23500
Highest PE OI (27 th OCT)	22000
PCR (27 th OCT)	1.02
Key Supply Zones	22800, 23400
Key Demand Zones	22500, 22300


NIFTY50 closing (last 20 trading sessions)



BANK NIFTY

Spot	55481.05
Futures	55778.20
Highest CE OI (27 th OCT)	58000
Highest PE OI (27 th OCT)	55000
PCR (27 th OCT)	1.06
Key Supply Zones	55800, 56200
Key Demand Zones	55000, 54700

BANK NIFTY closing (last 20 trading sessions)





Sector-wise Performance

Index	LTP	1 Day	1 Week	1 Month	1 Day vs Nifty50	1 Week vs Nifty50	1 Month vs Nifty50
Nifty India Defence	9,250.50	1.41%	0.38%	1.16%	In Line	In Line	Out-performing
Nifty Infrastructure	8,578.50	0.93%	-1.72%	-3.73%	Under-performing	Strong Under-performance	Under-performing
Nifty Energy	35,975.90	0.33%	-1.93%	-3.16%	Strong Under-performance	Strong Under-performance	Under-performing
Nifty Financial Services	25,228.55	1.46%	1.25%	0.61%	In Line	Out-performing	Out-performing
Nifty IT	29,830.10	5.22%	7.47%	0.93%	Strong Out-performance	Strong Out-performance	Out-performing
Nifty Realty	829.95	2.46%	0.89%	1.93%	Out-performing	In Line	Out-performing
Nifty FMCG	44,731.15	1.40%	-0.16%	-0.22%	In Line	Under-performing	Out-performing
Nifty Pharma	26,075.00	-0.01%	-1.37%	-0.43%	Strong Under-performance	Under-performing	Out-performing
Nifty Healthcare	15,860.65	0.08%	-1.24%	-2.69%	Strong Under-performance	Under-performing	In Line
Nifty Oil & Gas	10,349.60	0.49%	-2.57%	-4.14%	Strong Under-performance	Strong Under-performance	Under-performing
Nifty Auto	25,391.85	1.23%	1.01%	-5.10%	Under-performing	In Line	Under-performing
Nifty Metal	12,088.25	1.15%	-1.78%	-4.59%	Under-performing	Strong Under-performance	Under-performing
Nifty PSU Bank	8,146.55	1.44%	0.72%	-0.15%	In Line	In Line	Out-performing
Nifty Private Bank	27,324.35	0.74%	0.77%	0.94%	Under-performing	In Line	Out-performing
Nifty Bank	55,481.05	1.03%	0.77%	-0.56%	Under-performing	In Line	Out-performing
Nifty Consumer Durables	36,496.45	1.56%	0.45%	-3.86%	In Line	In Line	Under-performing

Stocks to watch: HAVELLS, SHRIRAMFIN, TECHM, WAAREEENER.

Stocks in F&O ban: AMBUJACEM, KAYNES.



KEY MOVING AVERAGES (NIFTY50 STOCKS)

Symbol	LTP	%Change	20 DSMA	50 DSMA	200 DSMA
ADANIENT	2695.00	2.47	2855.50	2949.28	2583.24
ADANIPTS	1763.00	0.51	1767.90	1724.09	1636.39
APOLLOHOSP	7871.00	1.23	8434.57	8660.05	8049.77
ASIANPAINT	2376.00	1.93	2403.49	2544.17	2548.14
AXISBANK	1268.40	1.23	1235.45	1243.59	1284.70
BAJAJ_AUTO	10318.00	2.83	10754.45	11378.94	10235.32
BAJAJFINSV	1755.70	2.08	1779.03	1915.56	1876.28
BAJFINANCE	982.75	2.66	987.12	1045.34	975.43
BEL	380.00	1.63	386.00	398.31	417.48
BHARTIARTL	1806.50	1.56	1805.82	1867.58	1900.89
BSE	3375.40	1.36	3236.05	3328.90	3325.24
CIPLA	1329.60	1.40	1356.81	1398.80	1374.31
COALINDIA	408.50	0.91	418.16	414.34	433.67
DRREDDY	1240.00	0.86	1202.01	1184.68	1244.73
EICHERMOT	7163.00	0.62	7233.22	7651.15	7401.30
ETERNAL	320.45	-0.79	326.45	323.26	277.88
GRASIM	2912.00	1.89	3061.67	3197.20	2978.38
HCLTECH	1326.00	8.42	1240.28	1286.51	1340.07
HDFCBANK	714.00	1.29	718.55	719.79	806.64
HDFCLIFE	560.00	0.13	542.21	540.89	614.78
HINDALCO	902.25	2.24	948.76	997.81	980.59
HINDUNILVR	1875.50	3.01	1897.64	1974.15	2171.41
ICICIBANK	1360.20	1.51	1337.23	1389.02	1353.15
INDIGO	4800.40	0.11	4899.07	5069.61	4820.15
INFY	1062.10	4.13	1026.33	1090.51	1245.01

Symbol	LTP	%Change	20 DSMA	50 DSMA	200 DSMA
ITC	261.00	1.20	264.04	268.60	298.91
JIOFIN	217.80	2.04	221.36	235.69	246.49
JSWSTEEL	1176.60	0.31	1241.57	1277.69	1239.45
KOTAKBANK	439.00	-0.99	419.63	411.53	399.97
LT	3675.00	1.31	3781.83	3929.52	3955.66
M&M	2864.40	1.83	2943.54	3181.36	3251.75
MARUTI	11245.00	-0.62	11825.95	12818.00	13794.65
MAXHEALTH	861.00	-0.57	972.44	1003.05	1026.90
NESTLEIND	1334.00	0.70	1346.09	1417.76	1364.47
NTPC	311.00	0.32	321.41	330.80	357.25
ONGC	222.65	1.20	229.22	233.75	256.08
POWERGRID	250.50	0.60	259.84	265.40	283.44
RELIANCE	1166.70	0.67	1207.35	1266.29	1350.78
SBILIFE	1687.20	0.38	1721.05	1757.84	1872.17
SBIN	957.00	1.70	969.55	1015.00	1040.51
SHRIRAMFIN	988.00	6.31	975.58	1046.54	1009.03
SUNPHARMA	1770.70	0.61	1820.57	1878.06	1807.46
TATACONSUM	960.00	0.13	975.13	1021.64	1106.19
TATASTEEL	175.00	1.60	181.84	184.63	194.12
TCS	2269.30	6.79	2118.84	2246.16	2479.57
TECHM	1543.50	4.93	1532.80	1575.62	1517.05
TITAN	4487.00	1.98	4678.23	4900.61	4422.58
TMPV	285.85	0.49	290.84	310.83	342.40
TRENT	2987.80	2.57	2769.43	2866.38	2779.67
ULTRACEMCO	10750.00	2.19	10839.50	11282.58	11676.61



DISCLAIMER

Name of the Research Entity: BOB Capital Markets Limited

Registered office Address: 1704, B Wing, Parinee Crescenzo, G Block, BKC, Bandra East, Mumbai 400051

SEBI Research Analyst Registration No: INH000000040 (Perpetual)

SEBI Stock Broker Registration No: INZ000159332

SEBI Depository Participant Registration No: IN-DP-728-2022

SEBI Merchant Banker Registration No: INM000009926

Phone: +91-22-61389300

Name of the Compliance Officer: Mr. Sameer Khobrekar

Email ID: Compliance@bobcaps.in; Phone no.: +91-22-61389358

For any queries or grievances, you may contact the Grievance Officer.

Name of the Grievance Officer: Mr. Nilesh Mehta

Email ID: head-customer@bobcaps.in; Phone no: 92288 60945

Brand Name: BOBCAPS

Website: <https://www.bobcaps.in/>

CIN: U65999MH1996GOI098009

Investments in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

**Analyst certification**

Each of the analysts mentioned in this research report certify, with respect to the sections of the report for which they are responsible, that (1) all of the views expressed in this report accurately reflect his/her personal views about the subject company or companies and its or their securities, and (2) no part of his/her compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of BOB Capital Markets Limited (BOBCAPS).

Important disclosures

This product is a compilation of previously published research notes. To view the complete report along with the associated Analyst certifications and Company-specific disclosures, please click on the hyperlink accompanying each excerpt.

General disclaimers

BOBCAPS is engaged in the business of Stock Broking and Investment Banking. BOBCAPS is a member of the National Stock Exchange of India Limited and BSE Limited and is also a SEBI-registered Category I Merchant Banker. BOBCAPS is a wholly owned subsidiary of Bank of Baroda which has its various subsidiaries engaged in the businesses of stock broking, lending, asset management, life insurance, health insurance and wealth management, among others. BOBCAPS's activities have neither been suspended nor has it defaulted with any stock exchange authority with whom it has been registered in the last five years. BOBCAPS has not been debarred from doing business by any stock exchange or SEBI or any other authority. No disciplinary action has been taken by any regulatory authority against BOBCAPS affecting its equity research analysis activities. BOBCAPS prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, BOBCAPS prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that the analysts cover. Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. This material should not be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction. We are not soliciting any action based on this material. It is for the general information of BOBCAPS's clients. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice or recommendation in this material, clients should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice. BOBCAPS research reports follow rules laid down by Securities and Exchange Board of India and individuals employed as research analysts are separate from other employees who are performing sales trading, dealing, corporate finance advisory or any other activity that may affect the independence of its research reports. The price and value of the investments referred to in this material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. BOBCAPS does not provide tax advice to its clients, and all investors are strongly advised to consult with their tax advisers regarding any potential investment in certain transactions — including those involving futures, options, and other derivatives as well as non-investment-grade securities — that give rise to substantial risk and are not suitable for all investors. The material is based on information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied on as such. Opinions expressed are our current opinions as of the date appearing on this material only. We endeavour to update on a reasonable basis the information discussed in this material, but regulatory, compliance, or other reasons may prevent us from doing so. We and our affiliates, officers, directors, and employees, including persons involved in the preparation or issuance of this material, may from time to time have "long" or "short" positions in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein and may from time to time add to or dispose of any such securities (or investment). We and our affiliates may assume an underwriting commitment in the securities of companies discussed in this document (or in related investments), may sell them to or buy them from customers on a principal basis, and may also perform or seek to perform investment banking or advisory services for or relating to these companies and may also be represented in the supervisory board or any other committee of these companies. For the purpose of calculating whether BOBCAPS and its affiliates hold, beneficially own, or control, including the right to vote for directors, one per cent or more of the equity shares of the subject company, the holdings of the issuer of the research report is also included. BOBCAPS and its non-US affiliates may, to the extent permissible under applicable laws, have acted on or used this research to the extent that it relates to non-US issuers, prior to or immediately following its publication. Foreign currency denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment. In addition, investors in securities such as ADRs, the value of which are influenced by foreign currencies, effectively assume currency risk. In addition, options involve risks and are not suitable for all investors. Please ensure that you have read and understood the Risk disclosure document before entering into any derivative transactions. No part of this material may be (1) copied, photocopied, or duplicated in any form by any means or (2) redistributed without BOBCAPS's prior written consent. Company-specific disclosures under SEBI (Research Analysts) Regulations, 2014. The research analyst(s) or his/her relatives do not have any material conflict of interest at the time of publication of this research report. BOBCAPS or its research analyst(s) or his/her relatives do not have any financial interest in the subject company. BOBCAPS or its research analyst(s) or his/her relatives do not have actual/beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report. The research analyst(s) has not received any compensation from the subject company or third party in the past 12 months in connection with research report/activities. Compensation of the research analyst(s) is not based on any specific merchant banking, investment banking or brokerage service transactions. BOBCAPS or its research analyst(s) is not engaged in any market making activities for the subject company. The research analyst(s) has not served as an officer, director or employee of the subject company. BOBCAPS or its associates may have material conflict of interest at the time of publication of this research report. BOBCAPS's associates may have financial interest in the subject company. BOBCAPS's associates may hold actual / beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report. BOBCAPS or its associates may have managed or co-managed a public offering of securities for the subject company or may have been mandated by the subject company for any other assignment in the past 12 months.

BOBCAPS may have received compensation from the subject company in the past 12 months. BOBCAPS may from time to time solicit or perform investment banking services for the subject company. BOBCAPS or its associates may have received compensation from the subject company in the past 12 months for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory services in a merger or specific transaction. BOBCAPS or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months.

Other disclaimers

BOBCAPS and MAYBANK (as defined below) make no representation or warranty, express or implied, as to the accuracy or completeness of any information obtained from third parties and expressly disclaim the merchantability, suitability, quality and fitness of this report. The information in this report has not been independently verified, is provided on an “as is” basis, should not be relied on by you in connection with any contract or commitment, and should not be used as a substitute for enquiries, procedures and advice which ought to be undertaken by you. This report also does not constitute an offer or solicitation to buy or sell any securities referred to herein and you should not construe this report as investment advice. All opinions and estimates contained in this report constitute BOBCAPS’s judgment as of the date of this report and are subject to change without notice, and there is no obligation on BOBCAPS or MAYBANK to update this report upon issuance. This report and the information contained herein may not be reproduced, redistributed, disseminated or copied by any means without the prior consent of BOBCAPS and MAYBANK. To the full extent permitted by law neither BOBCAPS, MAYBANK nor any of their respective affiliates, nor any other person, accepts any liability howsoever arising, whether in contract, tort, negligence, strict liability or any other basis, including without limitation, direct or indirect, special, incidental, consequential or punitive damages arising from any use of this report or the information contained herein. By accepting this report, you agree and undertake to fully indemnify and hold harmless BOBCAPS and MAYBANK from and against claims, charges, actions, proceedings, losses, liabilities, damages, expenses and demands (collectively, the “Losses”) which BOBCAPS and/or MAYBANK may incur or suffer in any jurisdiction including but not limited to those Losses incurred by BOBCAPS and/or MAYBANK as a result of any proceedings or actions brought against them by any regulators and/or authorities, and which in any case are directly or indirectly occasioned by or result from or are attributable to anything done or omitted in relation to or arising from or in connection with this report.

Distribution into the United Kingdom (“UK”):

This research report will only be distributed in the United Kingdom, in accordance with the applicable laws and regulations of the UK, by Maybank Securities (London) Ltd (“MSL”) who is authorised and regulated by the Financial Conduct Authority (“FCA”) in the United Kingdom (MSL and its affiliates are collectively referred to as “MAYBANK”). BOBCAPS is not authorized to directly distribute this research report in the UK. This report has not been prepared by BOBCAPS in accordance with the UK’s legal and regulatory requirements. This research report is for distribution only to, and is solely directed at, selected persons on the basis that those persons: (a) are eligible counterparties and professional clients of MAYBANK as selected by MAYBANK solely at its discretion; (b) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended from time to time (the “Order”), or (c) fall within Article 49(2)(a) to (d) (high net worth companies, unincorporated associations, etc. as mentioned in the stated Article) of the Order; (all such persons together being referred to as “relevant persons”). This research report is directed only at relevant persons and must not be acted on or relied on by any persons who are not relevant persons. Any investment or investment activity to which this material relates is available only to relevant persons and will be engaged in only with relevant persons. The relevant person as recipient of this research report is not permitted to reproduce, change, remove, pass on, distribute or disseminate the data or make it available to third parties without the written permission of BOBCAPS or MAYBANK. Any decision taken by the relevant person(s) pursuant to the research report shall be solely at their costs and consequences and BOBCAPS and MAYBANK shall not have any liability of whatsoever nature in this regard.

No distribution into the US:

This report will not be distributed in the US and no US person may rely on this communication.

Other jurisdictions:

This report has been prepared in accordance with SEBI (Research Analysts) Regulations and not in accordance with local regulatory requirements of any other jurisdiction. In any other jurisdictions, this report is only for distribution (subject to applicable legal or regulatory restrictions) to professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions by Maybank Securities Pte Ltd. (Singapore) and / or by any broker-dealer affiliate or such other affiliate as determined by Malayan Banking Berhad. If the recipient of this report is not as specified above, then it should not act upon this report and return the same to the sender. By accepting this report, you agree to be bound by the foregoing limitations.